What the FDA labels say about taking them together
Dihydroergotamine and zolmitriptan
Zolmitriptan's FDA label of January 29, 2026 names dihydroergotamine in its contraindications section; the dihydroergotamine labels PlainMeds reads (4) do not name zolmitriptan. The zolmitriptan label: “Because these effects may be additive, use of ergotamine-containing or ergot-type medications and zolmitriptan within 24 hours of each other is contraindicated [ see Contraindications ].”
Check it at the source: the dihydroergotamine FDA label on DailyMed (effective March 6, 2025, Oceanside Pharmaceuticals); the zolmitriptan FDA label on DailyMed (effective January 29, 2026, Glenmark Pharmaceuticals Inc.,USA).
What does the dihydroergotamine label say about zolmitriptan?
Dihydroergotamine's label (effective March 6, 2025) and its 3 other brand-application labels do not name zolmitriptan in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Dihydroergotamine Mesylate), NDA020148 (Bausch), as published by Oceanside Pharmaceuticals, effective March 6, 2025 (SPL set 977de209-c53a-4cb4-9f3f-1e850600a9dc), via openFDA; the full label on DailyMed
What does the zolmitriptan label say about dihydroergotamine?
Zolmitriptan label, contraindicationsRecent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 , 7.3 ) ]
Zolmitriptan label, drug interactionsBecause these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and zolmitriptan within 24 hours of each other is contraindicated [ see Contraindications ( 4 ) ].
Zolmitriptan label (Amneal Pharmaceuticals NY LLC, April 30, 2019), contraindications… disease [see Warnings and Precautions (5.5) ] Uncontrolled hypertension [see Warnings and Precautions (5.8) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.1 , 7.3) ] Concurrent administration of an MAO-A inhibitor or recent discontinuation of a MAO-A inhibitor (that is within 2 weeks) [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] Known hypersensitivity to zolmitriptan (angioedema and anaphylaxis seen) [see Adverse Reactions (6.2) ] History of ischemic heart disease or coronary artery vasospasm (4) Symptomatic …
Source: FDA drug label (Zolmitriptan, NDA021450), Amneal Pharmaceuticals NY LLC, effective April 30, 2019 (SPL set 05a40502-149d-41bd-966e-771e937a955b), via openFDA
Source: FDA drug label (Zolmitriptan), Glenmark Pharmaceuticals Inc.,USA, effective January 29, 2026 (SPL set 333caafc-2e63-49f8-a0c6-534e528d228d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dihydroergotamine | Zolmitriptan | |
|---|---|---|
| Labeled for | Migraine | Migraine |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $29.44 per mL 4 mg/mL nasal spray | $1.02 per tablet 2.5 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once